BRIEF published on 06/30/2025 at 14:05, 9 months 4 days ago Promising Phase 1b Results for invIOs's APN401 Cell Therapy in Advanced Tumors Cell Therapy Phase 1b Trial InvIOs GmbH APN401 Advanced Tumors
BRIEF published on 06/30/2025 at 14:05, 9 months 4 days ago Résultats prometteurs de phase 1b pour la thérapie cellulaire APN401 d'invIOs dans les tumeurs avancées Thérapie Cellulaire InvIOs GmbH APN401 Essai De Phase 1b Tumeurs Avancées
PRESS RELEASE published on 06/30/2025 at 14:00, 9 months 4 days ago invIOs reports promising Phase 1b results for cell therapy APN401 in advanced solid tumors invIOs reports successful Phase 1b trial results for APN401 cell therapy in advanced solid tumors, showing safety and efficacy in late-stage cancer patients Solid Tumors Cell Therapy Phase 1b Trial InvIOs APN401
BRIEF published on 12/16/2024 at 15:05, 1 year 3 months ago InvIOs to Highlight Oncology Pipeline Progress at JP Morgan Week 2025 Oncology Cancer Research Cell Therapy Glioblastoma InvIOs GmbH
BRIEF published on 12/16/2024 at 15:05, 1 year 3 months ago InvIOs mettra en avant les progrès du pipeline oncologique lors de la JP Morgan Week 2025 Thérapie Cellulaire Oncologie Glioblastome Recherche Sur Le Cancer InvIOs GmbH
PRESS RELEASE published on 12/16/2024 at 15:00, 1 year 3 months ago invIOs to present progress across oncology pipeline during JP Morgan Week 2025 invIOs GmbH to present progress in oncology pipeline at JP Morgan Week 2025, including updates on glioblastoma treatments INV501 and INV441 in collaboration with DFCI Oncology Pipeline InvIOs GmbH JP Morgan Week 2025 Glioblastoma Treatments DFCI Collaboration
BRIEF published on 10/15/2024 at 10:35, 1 year 5 months ago InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations Biotechnology Fundraising Clinical Trials Immuno-oncology InvIOs GmbH
BRIEF published on 10/15/2024 at 10:35, 1 year 5 months ago InvIOS obtient un financement de série A de 8,2 millions d'euros pour des innovations en immuno-oncologie Biotechnologie Essais Cliniques Immuno-oncologie Collecte De Fonds InvIOs GmbH
PRESS RELEASE published on 10/15/2024 at 10:30, 1 year 5 months ago invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology invIOs GmbH raises €8.2 million in Series A funding to advance immuno-oncology pipeline progress through 2025, collaborating with Dana-Farber Cancer Institute Series A Funding Immuno-oncology Pipeline Progress InvIOs Dana-Farber Cancer Institute
BRIEF published on 07/17/2024 at 10:05, 1 year 8 months ago InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma Cancer Therapy Melanoma Preclinical Studies INV501 Glioblastoma
Published on 04/02/2026 at 22:00, 2 days 1 hour ago Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 2 days 5 hours ago Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 2 days 8 hours ago Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 2 days 8 hours ago Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 2 days 9 hours ago Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution
Published on 04/04/2026 at 10:07, 13 hours 32 minutes ago Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Published on 04/04/2026 at 02:05, 21 hours 34 minutes ago Blokees made its debut at 2026 Thailand Toy Expo, exhibiting multiple products
Published on 04/03/2026 at 18:00, 1 day 5 hours ago IEVA GROUP: IMPLEMENTATION OF A LIQUIDITY AGREEMENT WITH CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 18:00, 1 day 5 hours ago IEVA GROUP: MISE EN OEUVRE D’UN CONTRAT DE LIQUIDITE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 17:45, 1 day 5 hours ago Atbash Launches on Chromia to Enable Verifiable, User-Controlled AI Systems
Published on 04/03/2026 at 18:46, 1 day 4 hours ago Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 1 day 4 hours ago Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 1 day 5 hours ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 1 day 5 hours ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 1 day 5 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026
